Neurocrine Biosciences Inc (NBIX): Cash & Equivalents
$713.00M
As of 2025-12-31
$332.40M
As of 2026-06-30
+39.5%
3-year compound annual growth
+30.7%
5-year compound annual growth
+25.4%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $713.00M | +206.0% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $233.00M | -7.2% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $251.10M | -4.5% | 2025-02-10, Balance as of period end |
| 2022-12-31 | $262.90M | -22.9% | 2024-02-09, Balance as of period end |
| 2021-12-31 | $340.80M | +82.1% | 2023-02-09, Balance as of period end |
| 2020-12-31 | $187.10M | +66.6% | 2022-02-11, Balance as of period end |
| 2019-12-31 | $112.30M | -20.8% | 2021-02-05, Balance as of period end |
| 2018-12-31 | $141.71M | -44.4% | 2020-02-07, Balance as of period end |
| 2017-12-31 | $254.71M | +205.9% | 2019-02-08, Balance as of period end |
| 2016-12-31 | $83.27M | +12.2% | 2018-02-13, Balance as of period end |
| 2015-12-31 | $74.19M | +139.2% | 2018-02-13, Balance as of period end |
| 2014-12-31 | $31.01M | -30.8% | 2017-02-14, Balance as of period end |
| 2013-12-31 | $44.79M | -29.7% | 2016-02-11, Balance as of period end |
| 2012-12-31 | $63.75M | +27.2% | 2015-02-09, Balance as of period end |
| 2011-12-31 | $50.11M | -7.3% | 2014-02-11, Balance as of period end |
| 2010-12-31 | $54.05M | +44.8% | 2013-02-08, Balance as of period end |
| 2009-12-31 | $37.33M | n/a | 2012-02-09, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $839.00M | +26.4% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $2.60B | +34.7% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
Compare NBIX, EXEL, QGEN, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗